On April 12, 2023, Denovicon Therapeutics Founder & CEO, Scott Bembenek, will present on ‘Enhanced Active Learning by Combining Machine Learning and Structure-Based Methods’ at the Drug Discovery Chemistry Conference: Artificial Intelligence for Early Drug Discovery – Part 2 in San Diego, CA.
Categories
Recent Posts
- Denovicon Reports Discovery of DNT-1569: A Highly Selective Small Molecule PARP7 Inhibitor for Immuno-Oncology
- Denovicon Introduces Quantum Physics-Driven Generative AI For Multi-Objective Optimization of Small-Molecule Drugs
- Denovicon Renewed for the 3DEXPERIENCE Lab Accelerator
- Denovicon Therapeutics Joins ARPA-H Investor Catalyst Hub Spoke Network
- Re-Inventing Drug Discovery